HK Stock Market Move | GENFLEET-B(02595) has increased by over 15%. The research results of three innovative large and small molecule preclinical studies will be published at the 2026 AACR Annual Meeting.

Jinn Pharma (02595) surged more than 15%, and at the time of publication, it was up 15.54% at HK$30.04, with a trading volume of HK$50.94 million. On the news front, on March 20, according to Jinn Pharma's official message, the company announced that the preclinical research results of three new drugs (GFH276, GFS784, GFH603) in its pipeline were selected for the poster session of the 2026 American Association for Cancer Research (AACR) annual meeting. This year's AACR annual meeting will be held in San Diego, USA from April 17 to 22, 2026. Jinn Pharma's RAS therapy matrix focuses on the treatment of various selective and pan-RAS mutation tumors, and also continues to focus on potential targets of important co-mutations in the RAS pathway; the matrix contains small molecule targeted drugs related to the molecular morphology and multi-mechanism RAS pathway. The upcoming meeting will showcase the preclinical research data of three products: GFH276 (non-degradable molecular glue), GFS784 (novel conjugated drug, connecting functional antibodies and synergistic mechanism targeted drug payloads), and GFH603 (molecular glue covalent transformation activator).